The report stresses the need to tackle issues like misaligned rebates, slow uptake, and market viability to sustain biosimilars' benefits for health care, highlighting challenges in reimbursement and suggesting policy changes for a stable environment.
In its market sustainability for infused biosimilars report, IQVIA echoed the need to address issues regarding misaligned incentives regarding rebates, slow or limited uptake, and concerns about market viability, which will be crucial for ensuring the long-term sustainability of biosimilars and maximizing their benefits for the health care system.
The report was intended to create a baseline of foundational data to better understand biosimilar dynamics with a particular focus on infused biosimilars that fall under the Medicare Part B buy and bill program. Using various case studies, the researchers wanted to gain understanding into the key issues that can result in suboptimal functioning for the US biosimilar market.
Over the past decade, biosimilars of infused biologics have significantly reduced health care costs, particularly within Medicare, saving billions of dollars. However, challenges persist in the reimbursement and procurement systems, threatening the long-term sustainability of biosimilars. Biosimilar development can cost between $100 million and $300 million, and reimbursement dynamics, reliant on declining average selling prices (ASPs), may erode profitability over time. This raises concerns about sustained market participation and patient access.
The report highlighted several key issues that can lead to suboptimal uptake of biosimilars in the US, including:
Challenges such as rebate walls hindering uptake and net cost recovery dynamics for providers pose significant barriers. Additionally, commercial payer rebates and discounts can drive down ASP, potentially impacting manufacturer viability. Moreover, patient out-of-pocket costs remain similar between biosimilars and originators due to supplemental insurance, diminishing incentives for biosimilar adoption.
The researchers suggested that CMS adjust its existing payment policies through regulatory actions to enhance add-on payments and address issues with lagging ASP and the impact of rebates. There were also several policy actions recommended, including regulatory measures that address stakeholder concerns such as providers, manufacturers, the health system, and patients. These actions involved adjusting reimbursement mechanisms and ensuring financial viability for all involved parties.
Additionally, stakeholders were urged to continually refine the policy environment to create a sustainable biosimilar system that aligned incentives for switching to biosimilars, supported manufacturer investment in research and development, optimized savings for payers over the long term, and reduced out-of-pocket costs for patients.
By implementing these suggested approaches and addressing key issues, stakeholders could work together to ensure the ongoing sustainability of biosimilars in the US health care system, maintaining cost savings and improving access to biologic therapies.
The researchers concluded saying that the overall goal of policy changes should be to “create a financially predictable payment and reimbursement environment for all stakeholders involved to ensure long-term sustainability of biosimilars. The focus of policy actions is on CMS as these issues can be addressed more immediately through CMS actions and other policies can be discussed over time to address these issues for commercial plans.”
Reference
Long-term market sustainability for infused biosimilars in the U.S. IQVIA. January 2024. Accessed February 14, 2024. https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/long-term-market-sustainability-for-infused-biosimilars-in-the-us
BioRationality: Should mRNA Copies Be Filed as NDAs or Biosimilars?
November 4th 2024The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products could be reconsidered, suggesting they might be eligible for new drug applications (NDAs) or a hybrid biosimilar category due to their unique characteristics and increasing prevalence.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Competitive Pricing in Biosimilars: How Adalimumab Could Shape the Industry
Published: October 29th 2024 | Updated: October 29th 2024Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited patients and the health care sector.
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf
October 25th 2024At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence in ensuring the resilience of biosimilar and generic drug production.